We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Periodontal Rapid Diagnostic Test Could Calculate Risk for Heart and Lung Disease

By LabMedica International staff writers
Posted on 21 Oct 2022

Gum (periodontal) disease is caused by infection in the gums and is the leading cause of tooth loss. More...

It gets more common with age, and 50% of 60-year olds will have periodontal disease in at least a mild form. However, untreated gum disease also has wide-ranging and serious effects on the rest of the body, where it correlates with an inflammatory response that affects the course of disease in other conditions. In type 2 diabetes, it increases the risk of heart failure, in cardiovascular disease it increases the risk of stroke or heart failure, in rheumatoid arthritis it increases the severity of disease, while in emphysema (also known as chronic obstructive pulmonary disease or COPD), it increases the risk of irreversible step-changes in disease severity. For people with these conditions, early detection and treatment of gum disease is a priority. Gum disease is usually identified in the dentist’s chair, when dental hygienists or dentists look for indicators such as tooth movement, sensitivity, gum bleeding or swelling. Now, researchers developing a rapid test for gum disease expect the technology - a probe for use in point of care settings such as dental surgeries or pharmacies - to play a pivotal role in early detection of heart or lung disease, type 2 diabetes and rheumatoid arthritis.

Researchers from the University of Birmingham (Edgbaston, UK) have devised a new technique that could provide a rapid and accurate assessment of both the presence and extent of gum disease from a sample of saliva that can be taken in any healthcare setting. Their method consists of a specialized probe and a detector that provides a quantitative measurement of biomarkers that indicate both the presence of gum disease and its severity. The biomarker panel was identified and validated by a team of researchers. The researchers have also received funding to develop a prototype of the new device, which is expected to be available within a year. In the long-term, the researchers expect to develop a probe that is small enough to be inserted into the space between gums and teeth, allowing dentists to collect fluid from specific areas in the mouth, and accurately identify the site of infection.

“We believe the device we are prototyping will be the first dental probe that can identify periodontal disease in this way,” said Professor Tim Albrecht, School of Chemistry, University of Birmingham. “It will detect periodontitis quickly and easily in a variety of healthcare settings, opening up opportunities for monitoring and early intervention in the patients with comorbid disease, who would benefit most from rapid treatment for periodontitis.”

“The ability to detect and profile disease biomarkers in real time will allow monitoring for disease severity, and in particular the transition between milder and more severe forms of gum disease,” added Dr. Melissa Grant, School of Dentistry, University of Birmingam. “This will benefit not only dental health, but also reduce costs and capture patients for whom periodontal treatment may, in the long run, be life-saving.”

Related Links:
University of Birmingham 


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.